Patents by Inventor Stephen L Madden

Stephen L Madden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150315269
    Abstract: To gain a better understanding of breast tumor angiogenesis, breast endothelial cells (ECs) were isolated and evaluated for gene expression patterns. When transcripts from breast ECs derived from normal and malignant breast tissues were compared, genes that were specifically elevated in tumor-associated breast endothelium were revealed. These results confirm that neoplastic and normal endothelium in human breast are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.
    Type: Application
    Filed: July 15, 2015
    Publication date: November 5, 2015
    Inventors: Saraswati SUKUMAR, Stephen L. MADDEN
  • Publication number: 20140056911
    Abstract: To gain a better understanding of breast tumor angiogenesis, breast endothelial cells (ECs) were isolated and evaluated for gene expression patterns. When transcripts from breast ECs derived from normal and malignant breast tissues were compared, genes that were specifically elevated in tumor-associated breast endothelium were revealed. These results confirm that neoplastic and normal endothelium in human breast are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.
    Type: Application
    Filed: October 29, 2013
    Publication date: February 27, 2014
    Applicants: Genzyme Corporation, The Johns Hopkins University
    Inventors: Saraswati SUKUMAR, Stephen L. MADDEN
  • Patent number: 8568985
    Abstract: To gain a better understanding of breast tumor angiogenesis, breast endothelial cells (ECs) were isolated and evaluated for gene expression patterns. When transcripts from breast ECs derived from normal and malignant breast tissues were compared, genes that were specifically elevated in tumor-associated breast endothelium were revealed. These results confirm that neoplastic and normal endothelium in human breast are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: October 29, 2013
    Assignees: Genzyme Corporation, The Johns Hopkins University
    Inventors: Saraswati Sukumar, Stephen L. Madden
  • Patent number: 8067240
    Abstract: The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: November 29, 2011
    Assignees: Esoterix Genetic Laboratories, LLC, Johns Hopkins University School of Medicine
    Inventors: Jin Jen, Gary A. Beaudry, Stephen L. Madden, Arthur H. Bertlesen, David Sidransky
  • Publication number: 20110262350
    Abstract: To gain a better understanding of breast tumor angiogenesis, breast endothelial cells (ECs) were isolated and evaluated for gene expression patterns. When transcripts from breast ECs derived from normal and malignant breast tissues were compared, genes that were specifically elevated in tumor-associated breast endothelium were revealed. These results confirm that neoplastic and normal endothelium in human breast are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.
    Type: Application
    Filed: July 5, 2011
    Publication date: October 27, 2011
    Applicants: THE JOHNS HOPKINS UNIVERSITY, GENZYME CORPORATION
    Inventors: Saraswati SUKUMAR, Stephen L. MADDEN
  • Publication number: 20110091892
    Abstract: The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.
    Type: Application
    Filed: November 22, 2010
    Publication date: April 21, 2011
    Inventors: Jin Jen, Gary A. Beaudry, Stephen L. Madden, Arthur H. Bertlesen, David Sidransky
  • Patent number: 7846667
    Abstract: The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: December 7, 2010
    Assignees: Genzyme Corporation, Johns Hopkins University
    Inventors: Jin Jen, Gary A. Beaudry, Stephen L. Madden, Arthur H. Bertlesen, David Sidransky
  • Patent number: 7709202
    Abstract: We used hierarchical clustering to examine gene expression profiles generated by serial analysis of gene expression (SAGE) in a total of nine normal lung epithelial cells and non-small cell lung cancers (NSCLC). Separation of normal and tumor samples, as well as histopathological subtypes, was evident using the 3,921 most abundant transcript tags. This distinction remained when just 115 highly differentially expressed transcript tags were used. Furthermore, these 115 transcript tags clustered into groups that were suggestive of the unique biological and pathological features of the different tissues examined. Adenocarcinomas were characterized by high-level expression of small airway-associated or immunologically related proteins, while squamous cell carcinomas overexpressed genes involved in cellular detoxification or antioxidation.
    Type: Grant
    Filed: July 27, 2007
    Date of Patent: May 4, 2010
    Assignees: The Johns Hopkins University, Genzyne Corporation, The U.S.A. as represented by the Secretary of the HHS
    Inventors: Mariana Nacht, Tatiana Dracheva, David Sidransky, Stephen L Madden, Jin Jen
  • Publication number: 20100062443
    Abstract: The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.
    Type: Application
    Filed: August 20, 2009
    Publication date: March 11, 2010
    Inventors: Jin Jen, Gary A. Beaudry, Stephen L. Madden, Arthur H. Bertlesen, David Sidransky
  • Publication number: 20090117038
    Abstract: To gain a better understanding of breast tumor angiogenesis, breast endothelial cells (ECs) were isolated and evaluated for gene expression patterns. When transcripts from breast ECs derived from normal and malignant breast tissues were compared, genes that were specifically elevated in tumor-associated breast endothelium were revealed. These results confirm that neoplastic and normal endothelium in human breast are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.
    Type: Application
    Filed: November 12, 2008
    Publication date: May 7, 2009
    Applicants: Genzyme Corporation, The Johns Hopkins University
    Inventors: Saraswati SUKUMAR, Stephen L. Madden
  • Publication number: 20040166527
    Abstract: This invention provides compositions and methods for the identification of lung cancer cells. In particular, polynucleotide sequences whose presence is indicative of lung cancer are disclosed. In addition, lung cancer can be identified by detecting the presence of the peptides encoded by these sequences. Antibodies to these peptides are also provided. Also included are gene delivery vehicles and host cells comprising these polynucleotides. Kits containing agents and instructions necessary to perform the screening and detecting methods are also provided.
    Type: Application
    Filed: April 1, 2004
    Publication date: August 26, 2004
    Inventors: Gary A. Beaudry, Stephen L. Madden, Arthur H. Bertelsen
  • Publication number: 20020115627
    Abstract: This invention provides methods for modulating phosphate homeostasis and renal phosphate transport by delivering agents that alter the expression of the FRP-4 gene or alter the activity of the FRP-4 protein. The methods of the invention are useful for modulating bone mineralization, renal phosphate transport, alleviating oncogenic osteomalacia-associated symptoms and treating phosphate homeostasis-related disease. The invention further provides methods for reducing phosphate re-absorption by delivering to a subject FRP-4 protein or polynucleotides that encode this protein. In addition, the invention provides methods for detecting and monitoring expression of the FRP-4 gene and modulating the phenotype of a neoplastic cell associated with oncogenic osteomalacia. Finally, the invention provides methods for screening candidate agents to identify compositions that modify the activity of the FRP-4 gene and protein.
    Type: Application
    Filed: July 19, 2001
    Publication date: August 22, 2002
    Inventors: Susan Schiavi, Stephen L. Madden, Parthasarathy Manavalan, Michael Levine, Suzanne Jan de Beur